title: Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
abstract: OBJECTIVE
  For patients with relapsed or refractory aggressive lymphoma, we hypothesized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effective as and less toxic than standard treatment.
  
  
  METHODS
  We randomly assigned 619 patients with relapsed/refractory aggressive lymphoma to treatment with gemcitabine, dexamethasone, and cisplatin (GDP) or to dexamethasone, cytarabine, and cisplatin (DHAP). Patients with B-cell lymphoma also received rituximab. Responding patients proceeded to stem-cell collection and ASCT. Coprimary end points were response rate after two treatment cycles and transplantation rate. The noninferiority margin for the response rate to GDP relative to DHAP was set at 10%. Secondary end points included event-free and overall survival, treatment toxicity, and quality of life.
  
  
  RESULTS
  For the intention-to-treat population, the response rate with GDP was 45.2%; with DHAP the response rate was 44.0% (95% CI for difference, -9.0% to 6.7%), meeting protocol-defined criteria for noninferiority of GDP (P = .005). Similar results were obtained in a per-protocol analysis. The transplantation rates were 52.1% with GDP and 49.3% with DHAP (P = .44). At a median follow-up of 53 months, no differences were detected in event-free survival (HR, 0.99; stratified log-rank P = .95) or overall survival (HR, 1.03; P = .78) between GDP and DHAP. Treatment with GDP was associated with less toxicity (P < .001) and need for hospitalization (P < .001), and preserved quality of life (P = .04).
  
  
  CONCLUSIONS
  For patients with relapsed or refractory aggressive lymphoma, in comparison with DHAP, treatment with GDP is associated with a noninferior response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity and hospitalization, and superior quality of life.
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy. michael.crump@uhn.on.ca.
authors.forename: Michael
authors.initials: M
authors.lastname: Crump
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: John
authors.initials: J
authors.lastname: Kuruvilla
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Stephen
authors.initials: S
authors.lastname: Couban
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: David A
authors.initials: DA
authors.lastname: MacDonald
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Vishal
authors.initials: V
authors.lastname: Kukreti
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: C Tom
authors.initials: CT
authors.lastname: Kouroukis
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Morel
authors.initials: M
authors.lastname: Rubinger
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Kevin R
authors.initials: KR
authors.lastname: Imrie
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Federico
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Di Renzo
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Kang
authors.initials: K
authors.lastname: Howson-Jan
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Tara
authors.initials: T
authors.lastname: Baetz
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Leonard
authors.initials: L
authors.lastname: Kaizer
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Michael
authors.initials: M
authors.lastname: Voralia
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Olney
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: A Robert
authors.initials: AR
authors.lastname: Turner
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Sussman
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Annette E
authors.initials: AE
authors.lastname: Hay
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Marina S
authors.initials: MS
authors.lastname: Djurfeldt
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Ralph M
authors.initials: RM
authors.lastname: Meyer
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Bingshu E
authors.initials: BE
authors.lastname: Chen
authors.affiliation: Michael Crump, John Kuruvilla, and Vishal Kukreti, Princess Margaret Cancer Centre; Rena Buckstein and Kevin R. Imrie, Odette Cancer Centre and Sunnybrook Health Sciences Centre, Toronto; C. Tom Kouroukis, Jonathan Sussman, and Ralph M. Meyer, Margaret and Charles Juravinski Cancer Centre, Hamilton; Kang Howson-Jan, London Health Sciences Centre, London; Tara Baetz, Cancer Centre of Southeastern Ontario at Kingston General Hospital; Annette E. Hay, Marina S. Djurfeldt, Ralph M. Meyer, Bingshu E. Chen, and Lois E. Shepherd, NCIC Clinical Trials Group, Kingston; Leonard Kaizer, Credit Valley Hospital, Mississauga, Ontario; Stephen Couban and David A. MacDonald, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; Morel Rubinger, Cancercare Manitoba, Winnipeg, Manitoba; Michael Voralia, Saskatoon Cancer Centre, Saskatoon, Saskatchewan; Harold J. Olney, Centre Hospitalier de l'Université de Montréal-Hopital Notre Dame, Montreal, Quebec; A. Robert Turner, Cross Cancer Institute, Edmonton, Alberta, Canada; Massimo Federico, University of Modena and Reggio Emilia, Modena; Nicola Di Renzo, Ospedale Vito Fazzi, Leece, Italy.
authors.forename: Lois E
authors.initials: LE
authors.lastname: Shepherd
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D003841:Deoxycytidine; D003907:Dexamethasone; D002945:Cisplatin